Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy

@article{Marachelian2015ComparativePS,
  title={Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy},
  author={A. Marachelian and A. Desai and F. Balis and H. Katzenstein and M. Qayed and Michael Armstrong and Kathleen A. Neville and S. Cohn and M. Bush and R. Gunawan and A. Lim and M. Smith and L. Mary Smith},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2015},
  volume={77},
  pages={405 - 412}
}
  • A. Marachelian, A. Desai, +10 authors L. Mary Smith
  • Published 2015
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • AbstractPurposeDinutuximab (Unituxin™; ch14.18), a monoclonal antibody against disialoganglioside, improved survival as part of post-consolidation therapy for high-risk neuroblastoma. United Therapeutics Corporation (UTC) assumed ch14.18 production from the National Cancer Institute (NCI); this study evaluates pharmacokinetic comparability, safety, and tolerability of UTC and NCI products.MethodsIn this randomized, two-sequence crossover study, 28 patients aged ≤8 years with high-risk… CONTINUE READING
    13 Citations
    Dinutuximab: A Review in High-Risk Neuroblastoma
    • 18
    The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    • 3
    Dinutuximab in the treatment of neuroblastoma
    Dinutuximab in the treatment of neuroblastoma
    • 2
    • PDF
    Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children’s Oncology Group

    References

    SHOWING 1-10 OF 15 REFERENCES
    Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma
    • 25
    Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    • 1,040
    • Highly Influential
    • PDF
    Promising Therapeutic Targets in Neuroblastoma
    • 144
    • PDF
    Neuroblastoma: Therapeutic strategies for a clinical enigma.
    • 155
    • PDF
    Disialoganglioside Directed Immunotherapy of Neuroblastoma
    • 110
    Analytical characterization of ch14.18
    • 7
    Glycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies
    • 29
    • PDF